BCAB Stock Recent News

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights.

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 16+ companies and 20+ pipeline drugs in AXL Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence AXL Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve AXL Inhibitors. AXL Inhibitors Emerging Drugs Chapters This segment of the AXL Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and D

BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.19 per share. Each warrant will be exercisable beginning six months after issuance and will expire 5.5 years from the date of issuance. The combined offering price per share of common stock and accompanying warrant is $0.9520. The closing of the offering is expected to occur on or about December 20, 2024, subject to the satisfaction of customary closing conditions.

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024.

BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call.

BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Ozuriftamab Vedotin shows promising Phase 2 results and received FDA Fast Track Designation, enhancing its potential.

BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with Context Therapeutics providing some runway extension. The company's cash position poses a significant risk, necessitating future fundraising, and potentially leading to substantial dilution and market volatility.

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.